Hadasit Bio-Hldgs Lt (HADSY) 1.2100 $HADSY
Zentera Systems, Inc.(TM) and Accton Technology(TM) Announce a Partnership for an Integrated Cloud Solution Stack Reference Design Based on OpenStack®
PR Newswire - Tue Jan 28, 8:02AM CST
Zentera Systems, the creator of the Hybrid Cloud Management Platform that enables businesses to move, manage and secure applications on any private, public or hybrid cloud, today announced a technology partnership with Accton Technology. The goal of the partnership is to deliver a reference design allowing industry adoption of an open solution stack for future cloud applications.
Promethean Showcases Revolutionary New Portfolio of "Connected Classroom" Solutions at Bett 2014 Educational Technology Event
PR Newswire - Wed Jan 22, 7:30AM CST
Stand C116
KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.5M
PR Newswire - Wed Sep 11, 8:14AM CDT
Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by the Hadassah University Hospital, today announced that KAHR Medical Ltd. ("KAHR"
, a portfolio company in which Hadasit Bio hold approximately 55%, will raise $2.5M at a valuation of $13.5M pre-money. Of the investment, $1.65M will be invested by Flerie Invest AB, a company controlled by Thomas Eldered, co-owner of Recipharm (www.recipharm.com), one of the largest pharmaceutical Contract Development and Manufacturing Organizations (CDMO) in Europe. Sanofi, the third largest pharmaceutical company in the world, will maintain its current holdings with an investment of $500K and Hadasit Bio will invest an additional $200K. An additional $150K will be offered as a one year option to Flerie and Hadasit Bio.
Hadasit Bio-Holdings Ltd. to Present at the Third Annual Connecticut-Israel Technology Summit
PR Newswire - Wed Jun 05, 8:22AM CDT
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that Mr. Ophir Shahaf, Chief Executive Officer, will be presenting at the third annual Connecticut-Israel Technology Summit on June 12th at The Oakdale Theater in Wallingford, CT.
Hadasit Bio-Holdings receives funding from Israeli Ministry of Industry and Commerce Office of the Chief Scientist
M2 - Fri May 24, 5:52AM CDT
Hadasit Bio-Holdings Ltd (TASE:HDST) (OTC:HADSY) reported on Thursday the receipt of received significant funding from the Israeli Ministry of Industry and Commerce Office of the Chief Scientist (OCS) to support product development and advance clinical trials.
Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support
PR Newswire - Thu May 23, 2:22PM CDT
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company, Cell Cure Neurosciences Ltd., received significant funding from the Israeli Ministry of Industry and Commerce, Office of the Chief Scientist (OCS) to support product development and advance clinical trials. Cell Cure's development budget totaling NIS 11.5 million (over $3 million USD) was approved for a grant of close to 50% financial support.
Hadasit Bio-Holdings CEO Letter to Shareholders
PR Newswire - Tue Apr 09, 8:00AM CDT
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that it has released the following letter to its shareholders:
Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
PR Newswire - Thu Apr 04, 8:11AM CDT
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced today that one of its flagship portfolio companies, Enlivex Therapeutics, was awarded orphan drug status by the FDA for its ApoCell treatment. The orphan drug designation provides for seven years of exclusivity, guaranteeing no competition irrespective of patents and significant regulatory relief, which will likely shorten the marketing approval of the drug in the US and reduce costs.
Zentera Systems, Inc.(TM) and Accton Technology(TM) Announce a Partnership for an Integrated Cloud Solution Stack Reference Design Based on OpenStack®
PR Newswire - Tue Jan 28, 8:02AM CST
Zentera Systems, the creator of the Hybrid Cloud Management Platform that enables businesses to move, manage and secure applications on any private, public or hybrid cloud, today announced a technology partnership with Accton Technology. The goal of the partnership is to deliver a reference design allowing industry adoption of an open solution stack for future cloud applications.
Promethean Showcases Revolutionary New Portfolio of "Connected Classroom" Solutions at Bett 2014 Educational Technology Event
PR Newswire - Wed Jan 22, 7:30AM CST
Stand C116
KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.5M
PR Newswire - Wed Sep 11, 8:14AM CDT
Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by the Hadassah University Hospital, today announced that KAHR Medical Ltd. ("KAHR"
, a portfolio company in which Hadasit Bio hold approximately 55%, will raise $2.5M at a valuation of $13.5M pre-money. Of the investment, $1.65M will be invested by Flerie Invest AB, a company controlled by Thomas Eldered, co-owner of Recipharm (www.recipharm.com), one of the largest pharmaceutical Contract Development and Manufacturing Organizations (CDMO) in Europe. Sanofi, the third largest pharmaceutical company in the world, will maintain its current holdings with an investment of $500K and Hadasit Bio will invest an additional $200K. An additional $150K will be offered as a one year option to Flerie and Hadasit Bio. Hadasit Bio-Holdings Ltd. to Present at the Third Annual Connecticut-Israel Technology Summit
PR Newswire - Wed Jun 05, 8:22AM CDT
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that Mr. Ophir Shahaf, Chief Executive Officer, will be presenting at the third annual Connecticut-Israel Technology Summit on June 12th at The Oakdale Theater in Wallingford, CT.
Hadasit Bio-Holdings receives funding from Israeli Ministry of Industry and Commerce Office of the Chief Scientist
M2 - Fri May 24, 5:52AM CDT
Hadasit Bio-Holdings Ltd (TASE:HDST) (OTC:HADSY) reported on Thursday the receipt of received significant funding from the Israeli Ministry of Industry and Commerce Office of the Chief Scientist (OCS) to support product development and advance clinical trials.
Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support
PR Newswire - Thu May 23, 2:22PM CDT
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company, Cell Cure Neurosciences Ltd., received significant funding from the Israeli Ministry of Industry and Commerce, Office of the Chief Scientist (OCS) to support product development and advance clinical trials. Cell Cure's development budget totaling NIS 11.5 million (over $3 million USD) was approved for a grant of close to 50% financial support.
Hadasit Bio-Holdings CEO Letter to Shareholders
PR Newswire - Tue Apr 09, 8:00AM CDT
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that it has released the following letter to its shareholders:
Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
PR Newswire - Thu Apr 04, 8:11AM CDT
Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced today that one of its flagship portfolio companies, Enlivex Therapeutics, was awarded orphan drug status by the FDA for its ApoCell treatment. The orphan drug designation provides for seven years of exclusivity, guaranteeing no competition irrespective of patents and significant regulatory relief, which will likely shorten the marketing approval of the drug in the US and reduce costs.
